Cancer Recurrence Articles & Analysis
8 articles found
Flotufolastat F 18 binds to prostate-specific membrane antigen (PSMA) (IC50= 4.4 nM) expressed on cells, including prostate cancer cells. In patients with recurrent prostate cancer who require local treatment, positron emission tomography (PET) with an 18F-labeled ligand provides accurate diagnostic imaging. The 18F group in Flotufolastat is a ...
BioMark Diagnostics Inc. is a Canadian-based cancer diagnostic company with head office located in Richmond, British Columbia and operating lab in Quebec City, Quebec. ...
Abstract We developed a series of models to predict the likelihood of recurrence and the response to chemotherapy for the personalized treatment of stage I and II colorectal cancer patients. A recurrence prediction model was developed from 235 stage I/II patients. ...
Abstract Background Cancer genomic signatures may vary using different platforms. We compared the differential gene expression in non-small cell lung cancer (NSCLC) between two platforms in order to find the most relevant genomic signatures of tumor recurrence. Materials and Methods We analyzed gene expression in frozen lung ...
A variety of targeting enrichment kits have been developed to monitor the onset or recurrence of cancer, tumor burden and evolution, including the development of therapeutic resistance. ...
Traditional immunotherapies, such as immune-activating cytokine therapy, checkpoint inhibition, engineered T-cells, etc., do not directly destroy cancer cells, but completely depend on activating the immune system. NIR-PIT can selectively destroy cancer cells while activating the body's immune response. ...
A fibre-optic probe can detect errant cancer cells within healthy tissue during brain tumour surgery with close to 100 per cent accuracy and sensitivity, reducing the risk of recurrence and thereby increasing a patient’s survival time, say the Canadian researchers who developed the device. ...
Cancer therapy should aim to prevent recurrent disease. Surgery and toxic treatments remove only symptoms associated with cancer without trying to intervene in the aetiology, therefore the disease may recur. The autologous cancer vaccine supplemented with bio-modulation might fulfil requirements for effective tumour therapy. ...